Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Selskabsmeddelelse

Klaria Pharma Holding AB: Klaria Interim Report Q3 2024

Klaria Pharma Holding
Download udgivelse

Klaria Interim Report Q3 2024

1 July - 30 September 2024

Third quarter of 2024

The group in total

- Net sales 0.0 MSEK (0.6 MSEK)

- Other income 0.0 MSEK (0.0 MSEK)

- R&D expenses for the quarter amounted to 1 MSEK (7.4 MSEK)

- Profit after tax amounted to -7.9 MSEK (-10.8 MSEK)

- Earnings per share for the quarter amounted to -0.06 SEK (-0.10 SEK)

- Cash flow from operating activities amounted to -3.8 MSEK (-7.3 MSEK)

- Liquid assets on the balance sheet date amounted to 0.5 MSEK (2.3 MSEK)

- Equity as of September 30 amounted to 12.9 MSEK (50.7 MSEK)

The period January- September 2024

The group in total

- Net sales 0.0 MSEK (7.1 MSEK)

- Other income 0.0 MSEK (0.2 MSEK)

- R&D expenses for the quarter amounted to 2.5 MSEK (23.0 MSEK)

- Profit after tax amounted to -32.2 MSEK (-26.3 MSEK)

- Earnings per share for the period amounted to -0.26 SEK (-0.27 SEK)

- Cash flow from operating activities amounted to -13.2 MSEK (-18.6 MSEK)

Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.